ATE526394T1 - Verfahren zur expansion von cd4+ cd25+ t regulatory zellen - Google Patents

Verfahren zur expansion von cd4+ cd25+ t regulatory zellen

Info

Publication number: ATE526394T1
Authority: AT; Austria
Prior art keywords: expansion; regulatory cells; cell; regulatory; mediated
Prior art date: 2005-02-25

Application number

AT06727566T

Other languages

English (en)

Inventor

Manuela Battaglia

Maria Grazia Roncarolo

Original Assignee

San Raffaele Centro Fond

Fond Telethon

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-25

Filing date

2006-02-24

Publication date

2011-10-15

2006-02-24 Application filed by San Raffaele Centro Fond, Fond Telethon filed Critical San Raffaele Centro Fond

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526394T1 publication Critical patent/ATE526394T1/de

Links

101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 title abstract 2
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 title abstract 2
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
210000003289 regulatory T cell Anatomy 0.000 title 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Pregnancy & Childbirth (AREA)
Pain & Pain Management (AREA)

AT06727566T 2005-02-25 2006-02-24 Verfahren zur expansion von cd4+ cd25+ t regulatory zellen ATE526394T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0503936.7A GB0503936D0 (en)	2005-02-25	2005-02-25	Method
PCT/IB2006/001116 WO2006090291A2 (en)	2005-02-25	2006-02-24	Method for expanding cd4+ cd25+ t regulatory cells

Publications (1)

Publication Number	Publication Date
ATE526394T1 true ATE526394T1 (de)	2011-10-15

Family

ID=34430224

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06727566T ATE526394T1 (de)	2005-02-25	2006-02-24	Verfahren zur expansion von cd4+ cd25+ t regulatory zellen

Country Status (8)

Country	Link
US (2)	US8562974B2 (de)
EP (1)	EP1869163B1 (de)
JP (1)	JP5095420B2 (de)
AT (1)	ATE526394T1 (de)
AU (1)	AU2006217546B2 (de)
CA (1)	CA2598631C (de)
GB (1)	GB0503936D0 (de)
WO (1)	WO2006090291A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPWO2007037544A1 (ja) *	2005-09-30	2009-04-16	国立大学法人京都大学	制御性ｔ細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性ｔ細胞の製造方法
GB0603081D0 (en) *	2006-02-15	2006-03-29	Dynal Biotech Asa Oslo	Method
DK2205721T3 (en)	2007-10-17	2016-10-24	Txcell	TR1 cells mesenchymal stem cells and uses thereof
US8658159B2 (en) *	2008-06-30	2014-02-25	Versitech Limited	Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
CA2733203A1 (en) *	2008-08-05	2010-02-11	Emory University	Use of mtor inhibitors to enhance t cell immune responses
WO2012018930A1 (en) *	2010-08-03	2012-02-09	University Of Miami	Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy
WO2012131419A1 (en) *	2011-03-25	2012-10-04	Txcell	Method for using regulatory t cells in therapy
EP2797623A1 (de) *	2011-11-23	2014-11-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Für ein irrelevantes antigen spezifische population von immunregulatorischen t-zellen und ihre verwendung bei der vorbeugung oder behandlung von immunerkrankungen
US10092597B2 (en)	2014-01-14	2018-10-09	The University Of Hong Kong	Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice
PL3134432T3 (pl)	2014-04-25	2020-10-19	Bluebird Bio, Inc.	Promotor mnd chimeryczne receptory antygenowe
HUE049514T2 (hu)	2014-04-25	2020-09-28	Bluebird Bio Inc	Javított eljárások adoptív sejtterápiák kialakítására
SI3151672T1 (sl)	2014-06-06	2021-03-31	Bluebird Bio, Inc.	Izboljšani T-celični sestavki
ES2878449T3 (es)	2014-07-24	2021-11-18	2Seventy Bio Inc	Receptores antigénicos quiméricos de BCMA
HRP20191873T1 (hr)	2014-12-12	2020-01-24	Bluebird Bio, Inc.	Kimerni antigenski receptori
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
PL236046B1 (pl)	2015-12-17	2020-11-30	Gdanski Univ Medyczny	Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+
WO2018085690A1 (en)	2016-11-04	2018-05-11	Bluebird Bio, Inc.	Anti-bcma car t cell compositions
WO2018106885A1 (en)	2016-12-07	2018-06-14	East Carolina University	Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
JP7572025B2 (ja) *	2016-12-27	2024-10-23	リバーセル株式会社	抗原特異的制御性ｔ細胞調製方法
CN120324602A (zh) *	2025-06-12	2025-07-18	核工业总医院	一种双特异性细胞膜纳米粒及其制备方法与应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US551413A (en)		1895-12-17		Willakd b
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4316885A (en)	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4650803A (en)	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5023264A (en)	1990-07-16	1991-06-11	American Home Products Corporation	Rapamycin oximes
US5023263A (en)	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
US5221670A (en)	1990-09-19	1993-06-22	American Home Products Corporation	Rapamycin esters
US5130307A (en)	1990-09-28	1992-07-14	American Home Products Corporation	Aminoesters of rapamycin
US5233036A (en)	1990-10-16	1993-08-03	American Home Products Corporation	Rapamycin alkoxyesters
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5162333A (en)	1991-09-11	1992-11-10	American Home Products Corporation	Aminodiesters of rapamycin
US5151413A (en) *	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en)	1992-03-05	1993-01-05	American Home Products Corporation	Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en)	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5411967A (en)	1992-10-13	1995-05-02	American Home Products Corporation	Carbamates of rapamycin
US5480989A (en)	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5480988A (en)	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5489680A (en)	1992-10-13	1996-02-06	American Home Products Corporation	Carbamates of rapamycin
US5302584A (en)	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
US5434260A (en)	1992-10-13	1995-07-18	American Home Products Corporation	Carbamates of rapamycin
US5262423A (en)	1992-10-29	1993-11-16	American Home Products Corporation	Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en)	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en)	1993-04-23	1996-04-02	American Home Products Corporation	Biotin esters of rapamycin
US5378836A (en)	1993-10-08	1995-01-03	American Home Products Corporation	Rapamycin oximes and hydrazones
US5391730A (en)	1993-10-08	1995-02-21	American Home Products Corporation	Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en)	1993-10-08	1994-12-13	American Home Products Corporation	Rapamycin oximes
US5385908A (en)	1993-11-22	1995-01-31	American Home Products Corporation	Hindered esters of rapamycin
US5385909A (en)	1993-11-22	1995-01-31	American Home Products Corporation	Heterocyclic esters of rapamycin
US5385910A (en)	1993-11-22	1995-01-31	American Home Products Corporation	Gem-distributed esters of rapamycin
US5389639A (en)	1993-12-29	1995-02-14	American Home Products Company	Amino alkanoic esters of rapamycin
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5463048A (en)	1994-06-14	1995-10-31	American Home Products Corporation	Rapamycin amidino carbamates
US5491231A (en)	1994-11-28	1996-02-13	American Home Products Corporation	Hindered N-oxide esters of rapamycin
US5563145A (en)	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
US5780462A (en)	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US20050031611A1 (en) *	1998-05-08	2005-02-10	Beth Israel Deaconess Medical Center	Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
US20020013335A1 (en)	2000-06-16	2002-01-31	American Home Products Corporation	Method of treating cardiovascular disease
US20030147865A1 (en) *	2002-02-07	2003-08-07	Benoit Salomon	Cell therapy using immunoregulatory T-cells
WO2004050090A1 (en)	2002-11-29	2004-06-17	Maria Grazia Roncarolo	Rapamycin and il-10 for the treatment of immune diseases
CA2529244C (en) *	2003-06-12	2014-02-18	The Trustees Of The University Of Pennsylvania	Rapamycin resistant t cells and therapeutic uses thereof
US20050048587A1 (en) *	2003-07-17	2005-03-03	Tolerrx, Inc.	Methods for identifying tolerance modulatory compounds and uses therefor

2005
- 2005-02-25 GB GBGB0503936.7A patent/GB0503936D0/en not_active Ceased
2006
- 2006-02-24 EP EP06727566A patent/EP1869163B1/de not_active Expired - Lifetime
- 2006-02-24 JP JP2007556687A patent/JP5095420B2/ja not_active Expired - Lifetime
- 2006-02-24 AU AU2006217546A patent/AU2006217546B2/en not_active Expired
- 2006-02-24 WO PCT/IB2006/001116 patent/WO2006090291A2/en not_active Ceased
- 2006-02-24 AT AT06727566T patent/ATE526394T1/de not_active IP Right Cessation
- 2006-02-24 CA CA2598631A patent/CA2598631C/en not_active Expired - Lifetime
- 2006-02-26 US US11/815,080 patent/US8562974B2/en active Active
2013
- 2013-09-17 US US14/029,510 patent/US20140086889A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2006090291A2 (en)	2006-08-31
JP5095420B2 (ja)	2012-12-12
AU2006217546A1 (en)	2006-08-31
EP1869163B1 (de)	2011-09-28
WO2006090291A3 (en)	2007-03-01
CA2598631C (en)	2018-09-11
US20080279826A1 (en)	2008-11-13
CA2598631A1 (en)	2006-08-31
GB0503936D0 (en)	2005-04-06
JP2008531009A (ja)	2008-08-14
US8562974B2 (en)	2013-10-22
EP1869163A2 (de)	2007-12-26
AU2006217546B2 (en)	2009-10-29
US20140086889A1 (en)	2014-03-27

Legal Events

Date	Code	Title	Description
2012-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE526394T1 (de)	2011-10-15	Verfahren zur expansion von cd4+ cd25+ t regulatory zellen
ATE489465T1 (de)	2010-12-15	Gezielte integration in die ppp1r12c-position
TR201821029T4 (tr)	2019-01-21	Geliştirilmiş antı-IL-23p19 antikorları.
MX2009008918A (es)	2009-09-14	Activacion de celulas que presentan antigeno humano a traves de clec-6.
UA101301C2 (ru)	2013-03-25	ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
CY1117721T1 (el)	2017-05-17	Κυτταρα προελευσης αμνιακου υγρου
WO2008118392A3 (en)	2008-12-04	Synthetic cell platforms and methods of use thereof
DOP2011000274A (es)	2011-10-31	Proteinas de union a il-17
EP4461806A3 (de)	2025-02-12	Sc-b-zellen und zusammensetzungen und verfahren zur erzeugung davon
MX2008012754A (es)	2009-04-27	Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica.
ATE474617T1 (de)	2010-08-15	Medizinproduktsysteme
WO2010000127A9 (en)	2010-04-01	Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
EP4491726A3 (de)	2025-03-05	Proteinangereicherte mikrovesikel und verfahren zur herstellung und verwendung davon
ATE407138T1 (de)	2008-09-15	Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
ECSP077222A (es)	2007-03-29	Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
WO2012062810A3 (en)	2012-07-05	Cell culture medium and process for protein expression, said medium and process comprising a pam inhibitor
NZ584606A (en)	2012-08-31	An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
DE60239741D1 (de)	2011-05-26	Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe
WO2011119868A3 (en)	2011-12-22	Hyper-spatial methods for modeling biological events
MX2009008422A (es)	2009-08-18	Proceso para la preparacion de alquilpiridinas de 5-(1-alquiltio)2-sustituidas.
PL1945673T3 (pl)	2015-10-30	Ukierunkowywanie i śledzenie antygenów w żywych komórkach
AR075840A1 (es)	2011-04-27	Expresion aumentada de genes de transhidrogenasa y su utilizacion en la produccion de etanol.
MX2007002277A (es)	2007-07-10	Metodos para formar retinoides y usos de los mismos.
WO2004072262A3 (en)	2005-03-24	Cultured cd14+ antigen presenting cells
ES2479540T3 (es)	2016-05-20	Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades